Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Update

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) saw a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 225,376 shares, a decrease of 26.3% from the January 15th total of 305,750 shares. Currently, 9.2% of the company’s shares are sold short. Based on an average trading volume of 204,964 shares, the days-to-cover ratio is currently 1.1 days. Based on an average trading volume of 204,964 shares, the days-to-cover ratio is currently 1.1 days. Currently, 9.2% of the company’s shares are sold short.

Analysts Set New Price Targets

EKSO has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.50.

Ekso Bionics Price Performance

NASDAQ EKSO traded up $0.67 on Monday, reaching $9.87. 228,329 shares of the stock traded hands, compared to its average volume of 183,832. Ekso Bionics has a 12 month low of $2.73 and a 12 month high of $12.70. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The firm’s fifty day simple moving average is $7.62 and its 200 day simple moving average is $5.50. The company has a market cap of $25.86 million, a price-to-earnings ratio of -1.74 and a beta of 0.80.

Institutional Trading of Ekso Bionics

Hedge funds have recently made changes to their positions in the stock. Consolidated Portfolio Review Corp bought a new position in shares of Ekso Bionics in the third quarter valued at approximately $333,000. Citadel Advisors LLC bought a new stake in Ekso Bionics during the 3rd quarter valued at approximately $198,000. Geode Capital Management LLC grew its holdings in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares during the last quarter. Shay Capital LLC bought a new position in Ekso Bionics in the 3rd quarter worth approximately $67,000. Finally, Virtu Financial LLC acquired a new position in shares of Ekso Bionics during the third quarter worth approximately $57,000. 6.42% of the stock is owned by hedge funds and other institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.